Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 11Obesity 4Sarcopenia 3Polycystic Ovary Syndrome 3Neoplasms 3Melanoma 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Malnutrition 2Lymphoma, Follicular 2Colorectal Neoplasms 2Breast Carcinoma In Situ 2Wound Infection 1Weight Loss 1Urinary Bladder Neoplasms 1Surgical Wound Infection 1Stomach Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1Psoriasis 1Precancerous Conditions 1Postoperative Complications 1Polyps 1Phagocyte Bactericidal Dysfunction 1Pain 1Paget's Disease, Mammary 1Overweight 1Osteoarthritis 1Olfaction Disorders 1Non-alcoholic Fatty Liver Disease 1

Interventions

eicosapentaenoic acid ethyl ester 1Walk Test 1Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Huntington Disease × Docosahexaenoic Acids × Clear all
NCT00146211 2007-12-27

TREND-HD - A Trial of Ethyl-EPA (Miraxionâ„¢) in Treating Mild to Moderate Huntington's Disease

Amarin Neuroscience Ltd

Phase 3 Completed
300 enrolled
Lymphoid

Huntington Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡